Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest announcement is out from Abivax SA Sponsored ADR ( (ABVX) ).
On September 8, 2025, Abivax SA announced its financial results for the first half of 2025, revealing a significant increase in operating loss to EUR 93.7 million compared to the same period in 2024. The increase was driven by higher research and development expenses, particularly related to the company’s Crohn’s Disease clinical program and the expansion of its R&D team. Despite a decrease in sales and marketing expenses, the company’s net financial position deteriorated, with a cash position of EUR 60.9 million as of June 30, 2025, down from EUR 144.2 million at the end of 2024. However, Abivax successfully completed a public offering in July 2025, raising approximately EUR 597.2 million in net proceeds, which is expected to support its ongoing clinical programs and operational goals.
The most recent analyst rating on (ABVX) stock is a Buy with a $116.00 price target. To see the full list of analyst forecasts on Abivax SA Sponsored ADR stock, see the ABVX Stock Forecast page.
Spark’s Take on ABVX Stock
According to Spark, TipRanks’ AI Analyst, ABVX is a Neutral.
Abivax SA’s overall stock score is primarily impacted by its poor financial performance, characterized by operational losses and high leverage. While technical analysis shows bullish momentum, the valuation remains unattractive due to negative earnings. Without additional positive catalysts or improvements in profitability, the stock faces significant risks.
To see Spark’s full report on ABVX stock, click here.
More about Abivax SA Sponsored ADR
Abivax SA is a clinical-stage biotechnology company based in Paris, France, focused on developing therapeutics that leverage the body’s natural regulatory mechanisms to modulate inflammatory responses in patients with chronic inflammatory diseases.
Average Trading Volume: 1,517,971
Technical Sentiment Signal: Buy
Current Market Cap: $6.77B
See more data about ABVX stock on TipRanks’ Stock Analysis page.